Kentuckiana Pulmonary Associates

Louisville, Kentucky 40204

1 studies enrolling now · 36 studies all time

What they study most

Bronchiectasis, Carcinoma, Chronic Obstructive Pulmonary Disease, Chronic Thromboembolic Pulmonary Hypertension, Connective Tissue Disease-Associated Pulmonary Arterial Hypertension, Heart Failure With Preserved Ejection Fraction, Idiopathic Pulmonary Fibrosis, Portopulmonary Hypertension, Precancerous Conditions, Pulmonary Arterial Hypertension, Pulmonary Hypertension, Pulmonary Hypertension Associated With HFpEF

Studies at this site

• Pulmonary Hypertension Association Registry — Recruiting now
• Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD) — Stopped early
• Selexipag (ACT-293987) in Pulmonary Arterial Hypertension — Completed
• Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER — Stopped early
• Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST — Stopped early
• The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension — Completed
• Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States — Completed
• PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial — Completed
• A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants — Stopped early
• FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH) — Completed
• A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD) — Stopped early
• A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) — Completed
• Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH) — Completed
• Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) — Stopped early
• An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension — Completed
• An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension — Completed
• Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH — Completed
• Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction — Stopped early
• Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF — Stopped early
• Beraprost-314d Added-on to Tyvaso® (BEAT) — Completed
• Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy — Completed
• Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction — Completed
• Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument — Completed
• Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument — Stopped early
• Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program — Completed
• Early Diagnosis of Pulmonary Nodules — Completed
• Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension — Completed
• Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) — Stopped early
• Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl. — Completed
• Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies — Completed
• Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension — Completed
• Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis — Completed
• Long-term Study of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension Who Completed AIR001-CS05 — Stopped early
• A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH) — Stopped early
• Iloprost Power Disc-15 in Pulmonary Arterial Hypertension — Stopped early
• Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension — Completed